What defenses does Cosentyx (secukinumab) affect in older adults?
Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL‑17A). IL‑17A is part of the body’s signaling used to coordinate immune responses, including inflammation and recruitment of immune cells to sites of infection. By blocking IL‑17A, Cosentyx shifts immune activity away from IL‑17A–driven pathways that help protect against certain infections.
For many patients, this means the drug can modestly increase risk of some infections—especially those where IL‑17A plays a more direct protective role, such as mucocutaneous fungal infections (e.g., Candida-related issues). This risk exists regardless of age, but older adults can be more vulnerable overall because age is associated with changes in immune function (sometimes called immunosenescence).
Does Cosentyx weaken “natural defenses” more in the elderly?
Age can make immune responses less robust and slower to control infections, so older adults may experience infections more easily or have infections that take longer to resolve. Cosentyx adds an extra, targeted effect by reducing IL‑17A–dependent immune signaling.
Putting those together, the net effect is that the elderly may have a higher likelihood of infection compared with younger patients on the same medicine. Clinicians typically respond by monitoring closely, reviewing other risk factors (diabetes, chronic lung disease, prior recurrent infections), and watching for early signs of infection.
What infections are most relevant to IL‑17A blockade?
Because IL‑17A is involved in antifungal defense and inflammatory responses at mucosal surfaces, infections patients and clinicians watch for on Cosentyx commonly include:
- Candida (yeast) infections of the mouth or skin folds
- Other respiratory or systemic infections, based on a patient’s overall risk profile
If an infection occurs, guidance generally focuses on prompt medical evaluation and deciding whether to hold or continue therapy depending on infection severity.
How quickly do changes in immune defenses happen after starting Cosentyx?
Cosentyx affects IL‑17A signaling as soon as therapeutic drug levels are reached. In practical terms, the infection risk profile is something clinicians monitor from early in therapy and throughout treatment, not only after long exposure. The highest concern is usually when new symptoms appear (fever, worsening cough, burning/painful mouth sores, or symptoms suggesting yeast infection).
What should older patients watch for while on Cosentyx?
Patients (and caregivers) are typically advised to seek medical advice promptly if they notice signs of infection, such as:
- Fever, chills, or feeling suddenly unwell
- Worsening cough, shortness of breath, or new chest symptoms
- Painful or persistent mouth sores, white patches in the mouth, or symptoms of yeast infection
- Skin rashes that look infected or spread quickly
Because older adults can sometimes present atypically (for example, without a high fever), reporting early changes is important.
Are there ways clinicians reduce infection risk in older adults on Cosentyx?
Common risk-reduction steps include:
- Reviewing vaccination status and avoiding live vaccines when not appropriate
- Screening for latent infections when indicated by clinical practice
- Assessing baseline infection history and comorbidities that increase infection risk
- Coordinating with the prescribing clinician before starting other immunosuppressive medicines
If you tell me the patient’s age, the condition being treated (psoriatic arthritis, psoriasis, or another indication), and any history of recurrent infections, I can tailor what “natural defenses” concerns are most relevant and what monitoring typically matters most.